Mcl-1 and Bcl-xL levels predict responsiveness to dual MEK/Bcl-2 inhibition in B-cell malignancies.
Melvold K, Giliberto M, Karlsen L, Ayuda-Durán P, Hanes R, Holien T, Enserink J, Brown JR, Tjønnfjord GE, Taskén K, Skånland SS.
Melvold K, et al. Among authors: skanland ss.
Mol Oncol. 2022 Mar;16(5):1153-1170. doi: 10.1002/1878-0261.13153. Epub 2021 Dec 18.
Mol Oncol. 2022.
PMID: 34861096
Free PMC article.